Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Nuvation Bio Inc. (NUVB)

Nuvation Bio notes offering reaches $287.5 million after full over-allotment exercise

Neutral Impact 3 of 5 financing Written later

Nuvation Bio issued an additional $37.5 million of 0.75% convertible senior notes due 2032 on July 6, 2026, after underwriters fully exercised their option, bringing the total offering to $287.5 million. The company estimates net proceeds of about $277.6 million and plans to use the remaining proceeds for general corporate purposes after paying about $2.2 million for additional capped call transactions.

Key points

  • Additional notes of $37.5 million issued July 6, 2026; total offering $287.5 million
  • Estimated net proceeds of approximately $277.6 million, inclusive of the additional notes
  • Notes bear 0.75% annual interest, mature July 1, 2032, and are general unsecured obligations
  • Capped call cap price of $10.4580 per share, a premium of 80.0% over the June 25, 2026 closing price on the NYSE

The filing

CompanyNuvation Bio Inc. (NUVB)
Form8-K, current report
Filed with the SECJul 6, 2026, 5:15 PM ET
Accession number0001193125-26-296398

Items reported: 2.03 New Direct Financial Obligation8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 06, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.